How a Man Built a $1.8 Billion Company with AI ... and Why the Story Doesn't End There

Matthew Gallagher, 41 years old, launched Medvi in September 2024 with $20,000 of his own money and a dozen AI tools. By 2025, after its first full year of operation, his telehealth platform for weight loss drugs GLP-1 recorded $401 million in revenue, 250,000 active customers, and a net margin of 16.2% with around $65 million in profit. For 2026, the projection rises to $1.8 billion, with a current run rate exceeding $3 million a day. The full-time employees are two: Matthew and his brother Elliot.

The New York Times, which had direct access to the financial data for verification, published a profile of Medvi as an emblematic case of that category of ultra-efficient companies that OpenAI CEO Sam Altman had anticipated in 2024: billion-dollar businesses run by a single person, made possible by AI. The profile generated an immediate reaction in the tech sector.

How Medvi (Really) Works

Gallagher used ChatGPT, Claude, and Grok to develop the platform's code, Midjourney and Runway to generate advertising creatives, and AI chatbots to manage customer support. He also built AI-powered analytics dashboards to monitor performance in real-time. However, Medvi is not a pharmaceutical company: it does not have its own medical network, does not hold a pharmaceutical license, and does not produce anything. The entire clinical and logistical part is fully delegated to two suppliers: CareValidate for medical compliance and prescriptions, and OpenLoop Health for pharmacy, fulfillment, and shipping. Medvi controls the brand, the website, advertising spend, and checkout.

The starting price for the first month of medication is $179, in line with competitors like Hims and Ro. No external funding: the company is fully bootstrapped and has accumulated between $70 and $80 million in reinvested profits since it started.

Shadows Over the Model

In February 2026, just weeks before the profile published by the NYT, the FDA sent Medvi an official warning letter for misbranding violations: the site presented compounded versions of Ozempic and Mounjaro under the Medvi brand, falsely implying that the company was the manufacturer and leading consumers to believe that the products were FDA-approved when they are not. Medvi was one of 30 telehealth companies to receive similar letters in that round of enforcement.

According to the New York Times, OpenLoop Health then suffered a data breach lasting two days (January 7-8), exposing over 1.6 million patient records: names, addresses, birth dates, medical information, treatment details, and shipping tracking numbers. This company is the supplier that manages all of Medvi's clinical and pharmaceutical logistics.

The Structural Limitation

Medvi does not hold proprietary technology, does not have exclusive relationships with doctors or pharmacies, and does not have defendable barriers to entry: anyone with marketing skills and a contract with CareValidate or OpenLoop could replicate the model. Gallagher explicitly acknowledges this and points to execution speed and brand as the only competitive advantages. The $1.8 billion projection for 2026 assumes that the regulatory framework does not become further rigid, an increasingly difficult hypothesis to support in light of recent developments.